# A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease

> **NCT05709444** · PHASE2 · COMPLETED · sponsor: **Palatin Technologies, Inc** · enrollment: 16 (actual)

## Conditions studied

- Kidney Disease

## Interventions

- **DRUG:** Bremelanotide
- **DRUG:** RAAS inhibition therapy

## Key facts

- **NCT ID:** NCT05709444
- **Lead sponsor:** Palatin Technologies, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-26
- **Primary completion:** 2024-04-26
- **Final completion:** 2024-04-26
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2024-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05709444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05709444, "A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05709444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*